About Stemgent
Stemgent is a company based in Cambridge (United States) founded in 2008 was acquired by ReproCELL in September 2014.. Stemgent has raised $43.23 million across 9 funding rounds from investors including ReproCELL, Morgenthaler and Healthcare Ventures. Stemgent has completed 1 acquisition, including Asterand Bioscience. Stemgent operates in a competitive market with competitors including Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Straumann Group, among others.
- Headquarter Cambridge, United States
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Unlock access to complete
Unlock access to complete
Unlock access to complete
Funding Insights of Stemgent
Stemgent has successfully raised a total of $43.23M across 9 strategic funding rounds. The most recent funding activity was a Series B round of $11.3 million completed in August 2012. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 9
- Last Round Series B — $11.3M
-
First Round
First Round
(01 May 2008)
- Investors Count 2
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug, 2012 | Amount | Series B - Stemgent | Valuation |
investors |
|
| Jan, 2012 | Amount | Series B - Stemgent | Valuation |
investors |
|
| Oct, 2011 | Amount | Debt – Conventional - Stemgent | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Stemgent
Stemgent has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include ReproCELL, Morgenthaler and Healthcare Ventures. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital and private equity investment firm
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location | |
|
Leading global supplier of iPS-derived cells, stem cell reagents, human biofluids, and 3D cell culture.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Stemgent
Stemgent has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Asterand Bioscience. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Human tissue solutions for drug discovery research are supplied globally.
|
2000 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Stemgent
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Stemgent Comparisons
Competitors of Stemgent
Stemgent operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Straumann Group, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| domain | founded_year | HQ Location |
Biomanufacturing technologies are supplied for biopharma antibody and vaccine production.
|
|
| domain | founded_year | HQ Location |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| domain | founded_year | HQ Location |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| domain | founded_year | HQ Location |
Dental implants and regenerative dentistry products are developed.
|
|
| domain | founded_year | HQ Location |
RNA-editing technologies are provided for precision medicine applications.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Stemgent
Frequently Asked Questions about Stemgent
When was Stemgent founded?
Stemgent was founded in 2008.
Where is Stemgent located?
Stemgent is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Is Stemgent a funded company?
Stemgent is a funded company, having raised a total of $43.23M across 9 funding rounds to date. The company's 1st funding round was a Debt – Conventional of $584.81K, raised on May 01, 2008.
What does Stemgent do?
Stemgent was founded in 2008 in Cambridge, United States, within the biotechnology sector focused on stem cell research. Cellular reprogramming products and tissue-based research tools are provided through a portfolio that includes mRNA systems, cell culture media, antibodies, small molecules, cytokines, and iPS reprogramming services. The Induced Pluripotent Stem Cells business was acquired by ReproCELL USA on October 1, 2014.
Who are the top competitors of Stemgent?
Stemgent's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
How many acquisitions has Stemgent made?
Stemgent has made 1 acquisition, including Asterand Bioscience.
Who are Stemgent's investors?
Stemgent has 3 investors. Key investors include ReproCELL, Morgenthaler, and Healthcare Ventures.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.